News for Kaken Pharmaceutical Co., Ltd. (KKPCF)

Market Analysis by covering: Corcept Therapeutics Incorporated, AbbVie Inc, DBV Technologies, ACELYRIN Inc. Read 's Market Analysis on Investing.com

Shares of KalVista Pharmaceuticals, Inc. (KALV) were gaining around 5 percent in the pre-market activity on the Nasdaq, after the company announced Tuesday that its unit, KalVista Pharmaceuticals, Ltd.

- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and fiel

**media[575420,575421]**

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO ® and $100 Million PIPE Financing

These documents have been translated from a part of Japanese originals for reference purposes only. In the event of any discrepancy between these translated...

May 14, 2024 SEIKAGAKU CORPORATION Seikagaku Announces the Biologics License Application for SI-6603 Has Been...

April 9, 2024 SEIKAGAKU CORPORATION Seikagaku Announces an Academic Conference Presentation on...

Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical

The rise in the number of people suffering from cirrhosis can be attributed to rapidly changing lifestyles such as an increase in alcohol consumption and...

Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.  U.S. FDA accepted...

The skin grafting devices market is witnessing significant growth driven by an increasing number of wounds, including deep burns, skin cancer, and cases...

EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders NexoBrid® U.S. commercial launch... -Today at 04:04 pm- MarketScreener

/PRNewswire/ -- The onychomycosis treatment market size is set to grow by USD 1,776.53 million from 2022 to 2027. Also, the growth momentum will progress at a...